Development of a Transformation System for : Restoration of Glycogen Biosynthesis by Acquisition of a Plasmid Shuttle Vector
Chlamydia trachomatis remains one of the few major human pathogens for which there is no transformation system. C. trachomatis has a unique obligate intracellular developmental cycle. The extracellular infectious elementary body (EB) is an infectious, electron-dense structure that, following host cell infection, differentiates into a non-infectious replicative form known as a reticulate body (RB). Host cells infected by C. trachomatis that are treated with penicillin are not lysed because this antibiotic prevents the maturation of RBs into EBs. Instead the RBs fail to divide although DNA replication continues. We have exploited these observations to develop a transformation protocol based on expression of β-lactamase that utilizes rescue from the penicillin-induced phenotype. We constructed a vector which carries both the chlamydial endogenous plasmid and an E.coli plasmid origin of replication so that it can shuttle between these two bacterial recipients. The vector, when introduced into C. trachomatis L2 under selection conditions, cures the endogenous chlamydial plasmid. We have shown that foreign promoters operate in vivo in C. trachomatis and that active β-lactamase and chloramphenicol acetyl transferase are expressed. To demonstrate the technology we have isolated chlamydial transformants that express the green fluorescent protein (GFP). As proof of principle, we have shown that manipulation of chlamydial biochemistry is possible by transformation of a plasmid-free C. trachomatis recipient strain. The acquisition of the plasmid restores the ability of the plasmid-free C. trachomatis to synthesise and accumulate glycogen within inclusions. These findings pave the way for a comprehensive genetic study on chlamydial gene function that has hitherto not been possible. Application of this technology avoids the use of therapeutic antibiotics and therefore the procedures do not require high level containment and will allow the analysis of genome function by complementation.
Vyšlo v časopise:
Development of a Transformation System for : Restoration of Glycogen Biosynthesis by Acquisition of a Plasmid Shuttle Vector. PLoS Pathog 7(9): e32767. doi:10.1371/journal.ppat.1002258
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1002258
Souhrn
Chlamydia trachomatis remains one of the few major human pathogens for which there is no transformation system. C. trachomatis has a unique obligate intracellular developmental cycle. The extracellular infectious elementary body (EB) is an infectious, electron-dense structure that, following host cell infection, differentiates into a non-infectious replicative form known as a reticulate body (RB). Host cells infected by C. trachomatis that are treated with penicillin are not lysed because this antibiotic prevents the maturation of RBs into EBs. Instead the RBs fail to divide although DNA replication continues. We have exploited these observations to develop a transformation protocol based on expression of β-lactamase that utilizes rescue from the penicillin-induced phenotype. We constructed a vector which carries both the chlamydial endogenous plasmid and an E.coli plasmid origin of replication so that it can shuttle between these two bacterial recipients. The vector, when introduced into C. trachomatis L2 under selection conditions, cures the endogenous chlamydial plasmid. We have shown that foreign promoters operate in vivo in C. trachomatis and that active β-lactamase and chloramphenicol acetyl transferase are expressed. To demonstrate the technology we have isolated chlamydial transformants that express the green fluorescent protein (GFP). As proof of principle, we have shown that manipulation of chlamydial biochemistry is possible by transformation of a plasmid-free C. trachomatis recipient strain. The acquisition of the plasmid restores the ability of the plasmid-free C. trachomatis to synthesise and accumulate glycogen within inclusions. These findings pave the way for a comprehensive genetic study on chlamydial gene function that has hitherto not been possible. Application of this technology avoids the use of therapeutic antibiotics and therefore the procedures do not require high level containment and will allow the analysis of genome function by complementation.
Zdroje
1. SchachterJDawsonCR 1990 The epidemiology of trachoma predicts moreblindness in the future. Scand J Infect Dis Suppl 69 55 62
2. GerbaseACRowleyJTMertensTE 1998 Global epidemiology of sexuallytransmitted diseases. Lancet 351 Suppl 3 2 4
3. RockeyDDMatsumotoA 2000 The chlamydial developmental cycle. BrunYVShimketsLJ Prokaryotic Development Washington D.C. ASM Press 403 425
4. WardME 1983 Chlamydial classification, development and structure. Br Med Bull 39 109 115
5. FieldsKAHackstadtT 2002 The Chlamydial Inclusion: Escape from the endocytic pathway. Annu Rev Cell Dev Biol 18 221 245
6. SkiltonRJCutcliffeLTBarlowDWangYSalimO 2009 Penicillin induced persistence in Chlamydia trachomatis: high quality time lapse video analysis of the developmental cycle. PLoS One 4 e7723
7. StephensRSKalmanSLammelCFanJMaratheR 1998 Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science 282 754 759
8. Seth-SmithHMBHarrisSRPerssonKMarshPBarronA 2009 Co-evolution of genomes and plasmids within Chlamydia trachomatis and the emergence in Sweden of a new variant strain. BMC Genomics 10 239
9. RicciSCeveniniRCoscoEComanducciMRattiG 1993 Transcriptional analysis of the Chlamydia trachomatis plasmid pCT identifies temporally regulated transcripts, anti-sense RNA and σ70 -selected promoters. Mol Gen Genet 237 318 326
10. LiZChenDZhongYWangSZhongG 2008 The chlamydial plasmid-encoded protein pgp3 is secreted into the cytosol of Chlamydia-infected cells. Infect Immun 76 3415 3428
11. ClarkeIN 2010 Chlamydial transformation: facing up to the challenge. SchachterJByrneGICaldwellHDCherneskyMClarkeINMabeyDPaavonenJSaikkuPStarnbachMNStaryAStephensRSTimmsPWyrickPB Proceedings of the Twelfth International Symposium on Human Chlamydial Infections, Salzburg, Austria 295 304
12. KariLGoheenMMRandallLBTaylorLDCarlsonJH 2011 Generation of targeted Chlamydia trachomatis null mutants. Proc Natl Acad Sci U S A 108 7189 7193
13. BinetRMaurelliAT 2009 Transformation and isolation of allelic exchange mutants of Chlamydia psittaci using recombinant DNA introduced by electroporation. Proc Natl Acad Sci U S A 106 292 297
14. TamJEDavisCHWyrickPB 1994 Expression of recombinant DNA introduced into Chlamydia trachomatis by electroporation. Can J Microbiol 40 583 591
15. PetersonEMMarkoffBASchachterJde la MazaLM 1990 The 7.5-kb plasmid present in Chlamydia trachomatis is not essential for the growth of this microorganism. Plasmid 23 144 148
16. FarencenaAComanducciMDonatiMRattiGCeveniniR 1997 Characterization of a new isolate of Chlamydia trachomatis which lacks the common plasmid and has properties of Biovar trachoma. Infect Immun 65 2965 2969
17. StothardDRWilliamsJAVan der PolBJonesRB 1998 Identification of a Chlamydia trachomatis serovar E urogenital isolate which lacks the cryptic plasmid. Infect Immun 66 6010 6013
18. MatsumotoAIzutsuHMiyashitaNOhuchiM 1998 Plaque formation by and plaque cloning of Chlamydia trachomatis biovar trachoma. J Clin Microbiol 36 3013 3019
19. PickettMAEversonJSPeadPJClarkeIN 2005 The plasmids of Chlamydia trachomatis and Chlamydophila pneumoniae (N16): accurate determination of copy number and the paradoxical effect of plasmid-curing agents. Microbiology 151 893 903
20. O'ConnellCMAbdelrahmanYMGreenEDarvilleHKSairaK 2011 Toll-like receptor 2 activation by Chlamydia trachomatis is plasmid dependent, and plasmid-responsive chromosomal loci are coordinately regulated in response to glucose limitation by C. trachomatis but not by C. muridarum. Infect Immun 79 1044 1056
21. O'ConnellCMNicksKM 2006 A plasmid-cured Chlamydia muridarum strain displays altered plaque morphology and reduced infectivity in cell culture. Microbiology 152 1601 1607
22. CarlsonJHWhitmireWMCraneDDWickeLVirtanevaK 2008 The Chlamydia trachomatis plasmid is a transcriptional regulator of chromosomal genes and a virulence factor. Infect Immun 76 2273 2283
23. ArmstrongJA 1967 Fine Structure of Lymphogranuloma Venereum Agent and the Effects of Penicillin and 5′ Fluorouracil. J Gen Microbiol 129 2001 2007
24. KramerMJGordonFB 1971 Ultra structural analysis of the effects of penicillin and chlortetracycline on the development of genital tract Chlamydia. Infect Immun 3 333 341
25. LambdenPRPickettMAClarkeIN 2006 The effect of penicillin on Chlamydia trachomatis DNA replication. Microbiology 152 2573 2578
26. SambrookJFritschEManiatisT 1989 Molecular Cloning A Laboratory Manual. New York Cold Spring Harbor Laboratory Press
27. SuchlandRJSandozKMJeffreyBMStammWERockeyDD 2009 Horizontal transfer of tetracycline resistance among Chlamydia spp. in vitro. Antimicrob Agents Chemother 53 4604 4611
28. SandozKMRockeyDD 2010 Antibiotic resistance in Chlamydiae. Future Microbiol 5 1427 1442
29. LiCHChengYWLiaoPLYangYTKangJJ 2010 Chloramphenicol causes mitochondrial stress, decreases ATP biosynthesis, induces matrix metalloproteinase-13 expression, and solid-tumor cell invasion. Toxicol Sci 116 140 150
30. WorkowskiKABermanS 2010 Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 59 1 110
31. SkippPRobinsonJO'ConnorCDClarkeIN 2005 Shotgun proteomic analysis of Chlamydia trachomatis. Proteomics 5 1558 1573
32. ThomsonNRHoldenMTGCarderCLennardNLockeySJ 2008 Chlamydia trachomatis: Genome sequence analysis of lymphogranuloma venereum isolates. Genome Res 18 161 171
33. KahaneSSarovI 1987 Cloning of a Chlamydial Plasmid: Its use as a probe and in vitro Analysis of enclosed Polypeptides. Curr Microbiol 14 225 228
34. SchachterJMeyerKF 1969 Lymphogranuloma venereum: II. Characterisation of some recently isolated strains. J Bacteriol 99 636 638
35. PeelingRWBrunhamRC 1991 Neutralization of Chlamydia trachomatis: Kinetics and Stoichiometry. Infect Immun 59 2624 2630
36. MandelMHigaA 1970 Calcium-dependent bacteriophage DNA infection. J Mol Biol 53 159 162
37. KadonagaJTGautierAEStrausDRCharlesADEdgeMD 1984 The role of the beta-lactamase signal sequence in the secretion of proteins by Escherichia coli. J Biol Chem 259 2149 2154
38. EkiciODKarlaAPaetzelMLivelyMOPeiD 2007 Altered -3 substrate specificity of Escherichia coli signal peptidase 1 mutants as revealed by screening a combinatorial peptide library. J Biol Chem 282 417 425
39. SkiltonRJCutcliffeLTPickettMALambdenPRFaneBA 2007 Intracellular parasitism of chlamydiae: specific infectivity of chlamydiaphage Chp2 in Chlamydophila abortus. J Bacteriol 189 4957 4959
40. EversonJSGarnerSAFaneBLiuB-LLambdenPR 2002 Biological Properties and Cell Tropism of Chp2, a Bacteriophage of the Obligate Intracellular Bacterium Chlamydophila abortus. J Bacteriol 184 2748 2754
41. HanahanD 1985 Techniques for Transformation of E.coli. GloverDM DNA cloning Oxford IRL Press 109 135
42. GrantGGNJesseJBloomFRHanahanD 1990 Differential plasmid rescue from transgenic mouse DNAs transformed inth Esherichia coli methylation-resistant mutants. Proc Natl Acad Sci USA 87 4645 4649
43. BanksJEddieBSchachterJMeyerKF 1970 Plaque Formation by Chlamydia in L Cells. Infect Immun 1 259 262
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2011 Číslo 9
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- Hostile Takeover by : Reorganization of Parasite and Host Cell Membranes during Liver Stage Egress
- HTLV-1 Propels Thymic Human T Cell Development in “Human Immune System” Rag2 gamma c Mice
- Exploiting and Subverting Tor Signaling in the Pathogenesis of Fungi, Parasites, and Viruses
- A Viral Ubiquitin Ligase Has Substrate Preferential SUMO Targeted Ubiquitin Ligase Activity that Counteracts Intrinsic Antiviral Defence